Navigation Links
KINAXO Completes Financing Round to Enhance Biomarker Development
Date:11/21/2009

Martinsried, Germany, November 20,2009 / b3c newswire / -KINAXO Biotechnologies GmbH announces the completion of a financing round, gaining two new investors in the company, Leifina and Conmit Invest. At the same time KINAXO reports that Jrgen Schumacher has been elected as a new member of the companys advisory board.


KINAXO shareholders Axel Ullrich, Hellmut Kirchner, Manfred Ferber as well as the companys institutional investors Mountain Partners, BioM, High-Tech Grnderfonds, the Max-Planck Society and the KfW ERP Start-Fonds also participated in this financing round. KINAXO will use the funds to develop novel biomarkers that allow stratification of cancer patients receiving targeted therapies.


KINAXOs CEO and co-founder Andreas Jenne said: There is little doubt that biomarkers will be one of the major drivers of pharmaceutical research and development in the 21st Century. Biomarkers have the potential to improve R&D efficiency and clinical success rates, save public health costs, and gain pharmaceutical companies a valuable advantage over their competitors. Following this trend we will make significant investments over the next few years to expand our phosphoproteomics services PhosphoScout and develop a novel class of biomarkers that help improve cancer therapies.


Horst Domdey, CEO of BioM, commented: KINAXO is in the right place at the right time. Today, biomarkers are more and more in demand to improve treatment options. With its unique phosphoproteomics platform that goes way beyond existing technologies, KINAXO is very well positioned in this rapidly growing market. Moreover, KINAXOs recent partnerships with Bayer and Roche underpin the industrys readiness to implement novel technologies turning personalized medicine into reality.

About KINAXO Biotechnologies GmbH
KINAXO is
'/>"/>

b3c newswire

Page: 1 2 3

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue
3. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
4. SyntheMed Completes $2.8 Million Equity Financing
5. Labwire Completes Its First Acquisition
6. bioMETRX, Inc. Completes Sequiam Asset Purchase
7. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
8. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
9. DOE Joint Genome Institute completes soybean genome
10. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
11. Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigations Next Generation Identification Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... containing carbon-halogen bonds are produced naturally across all kingdoms ... products with a broad range of biological activities. The ... a profound influence on their molecular properties. ... has been to find the late-stage, site-specific incorporation of ... replacing an sp C-H bond (one of the most ...
(Date:9/15/2014)... released today by the National Academy of Sciences, ... and strategies for the program and will guide ... years (2015-2020). In addition, the program announced ... in 2015, will include exploratory grants, early-career research ... $500 million, 30-year program to be run by ...
(Date:9/15/2014)... cognitive function may play roles in one,s musical aptitude, ... timbre, tone durations, and formal structure in music. , ... that extremes in musical aptitude (extreme capacity/no capacity) are ... having moderate aptitude. , "This is a typical feature ... and it is influenced to varying degrees by environmental ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... have discovered a gene in plants that disrupts fertilization ... both the female and male reproductive cells. Their ... in the journal Current Biology, has been named the ... properties. Mutations that do not allow fertilization are ...
... of Grenoble, in France, have discovered that ... by doxorubicin and trastuzumab exposures. The research ... protects against acute chemotherapy toxicity in isolated ... January 2008 issue of Experimental Biology and ...
... - A group of signaling proteins known as Wnt ... muscle and other tissues - depend on a complex ... tissue-building cell sites, according to a study at Cincinnati ... the Retromer Complex - breaks down, the delivery of ...
Cached Biology News:Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3A search for protection against chemotherapy cardiotoxicity 2Certain diseases, birth defects may be linked to failure of protein recycling system 2
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014  Ascendis Pharma A/S, a biotechnology company ... significant unmet medical needs, today announced positive interim ... to evaluate once-weekly TransCon Growth Hormone in children ... interim results will be presented at the 7th ... being held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... , Sept. 15, 2014   Global ... innovator of scientific products and services for satellite ... Acquisition Solution for Integrated Services (OASIS) from the ... GST was selected to provide the government best-value ... Small Business (SB) category in Pool 4. The ...
Breaking Biology Technology:Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Approval Shortly -- , , LAKE FOREST, Ill., June ... world leader in generic injectable pharmaceuticals, today announced that the ... granted summary judgment of non-infringement in Hospira,s favor with regard ... tentative approval from the U.S. Food and Drug Administration (FDA) ...
... LANSING, Mich., June 18 Fortune Magazine has named ... its annual list of the "40 best stocks to retire on." ... list in 2002, stating: "We wanted to assemble a diversified, dependable ... could soar when the market did but also hold steady during ...
... Optical Industry Ltd. (Nasdaq: SHMR ) a leading ... market, announced today that its annual report on Form 20-F, ... 31, 2008, as filed with the Securities and Exchange Commission ... www.shamir.co.il ). Shareholders may receive a hard copy of the ...
Cached Biology Technology:Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website 2
... Plates are designed for quick and easy ... plates feature two 0.25mm holes laser cut ... The wells remain liquid-tight during incubation of ... time the protein diffuses from the gel ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
... Enhancer does for enzyme-/substrate-based blotting what intensifying screens ... signal up to 10-fold (or one order of ... Blot Signal Enhancer membrane treatment is a simple, ... your current Western blotting protocol. The result is ...
... a multi-functional program that searches ... a sequence file for polymerase ... site-directed mutagenesis, and various hybridization ... and secondary structure of oligonucleotides ...
Biology Products: